Antilymphocyte antibodies in progressive systemic sclerosis.

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Scleroderma is an autoimmune disease characterized by fibrosis of skin and internal organs.
• Immunological abnormalities are frequently observed in scleroderma patients.
• The presence and specificity of antilymphocyte antibodies (ALA) in scleroderma remain incompletely understood.

Purpose of the Study:

• To investigate the presence and characteristics of antilymphocyte antibodies (ALA) in patients with scleroderma.
• To determine the specificity of detected ALA, particularly against T cells.
• To explore the potential relationship between ALA and the UCHT1 receptor on T cells.

Main Methods:

• Sera from 19 scleroderma patients were analyzed using indirect immunofluorescence assay.
• Antibody binding was assessed at different temperatures (0°C and 25°C).
• B and T cells were separated to determine antibody specificity, and a monoclonal antibody (UCHT1) was used to probe T cell receptors.

Main Results:

• Antilymphocyte antibodies (ALA) were detected in 47% of patients at 0°C and 27% at 25°C.
• Separation of lymphocytes confirmed anti-T cell specificity for the detected ALA.
• Significant heterogeneity in ALA binding was observed among patients and within individual sera.
• UCHT1 antibody partially or completely inhibited ALA binding in four patients, indicating receptor similarity.

Conclusions:

• Scleroderma is associated with the presence of cold-reactive anti-T cell specific ALA.
• The detected ALA exhibit heterogeneity and target T cells, potentially through receptors similar to the UCHT1 target.
• Further research is warranted to elucidate the pathogenic role of these cold-reactive anti-T cell ALA in scleroderma.